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Abstract
We present a simple text mining method that is easy to implement, requires minimal data collection and preparation,
and is easy to use for proposing ranked associations between a list of target terms and a key phrase. We call this method
KinderMiner, and apply it to two biomedical applications. The first application is to identify relevant transcription
factors for cell reprogramming, and the second is to identify potential drugs for investigation in drug repositioning.
We compare the results from our algorithm to existing data and state-of-the-art algorithms, demonstrating compelling
results for both application areas. While we apply the algorithm here for biomedical applications, we argue that the
method is generalizable to any available corpus of sufficient size.
Introduction
Many scientific discoveries are often subject to lengthy processes of trial and error before important and meaningful
results are found. For example:
1. In biology, determining a set of defined transcription factors for differentiating or reprogramming cell types
requires trying numerous combinations from lists of factors. The combinatorial growth of the search space
quickly leads to intractability.
2. In medicine, discovering off-label uses of approved drugs can take years of collecting observational data and
running post-approval trials. Once again, the search becomes time-consuming due to the enormous number of
pairs of drugs and effects.
3. Similarly in medicine, detecting adverse drug events can require extensive observational data to detect potential
correlations between drugs and events.
Because the search spaces are so large, proper prioritization of research directions in these cases is essential to reach-
ing novel discoveries quickly, but this requires both extensive breadth and depth of knowledge within the domain.
Furthermore, due to exponential growth in scientific literature,1,2 it is becoming continually more challenging to keep
up with current knowledge in any particular domain. We present a general text mining approach to address this pri-
oritization problem by ranking a list of target terms (e.g. transcription factors or drugs) by their association with a
key phrase (e.g. “embryonic stem cell” or “hypoglycemia”). This list provides researchers with a starting point for
entering the literature domain and prioritizing potential research directions, thereby accelerating the discovery process.
Our method is easy to implement, requires minimal data collection and preparation, and is easy to use.
To produce our ranked list of target terms associated with a key phrase, we leverage the vast collective knowledge
available within the published scientific and medical literature. We use simple keyword matching and document
counting to automatically identify significant correlations and rank them by their co-occurrence proportion. Owing to
its simplicity, we call our method KinderMiner.
While we can imagine several applications of our approach, we focus our attention on the two former examples given
above: determining important transcription factors for cell reprogramming and discovering off-label uses of approved
drugs. To assess our approach, we compare rankings produced by our approach with three cell reprogramming tasks
that have experimentally proven sets of defined factors from landmark publications. For fairness, we censor the
literature in our experiments to publications from roughly two years prior to the relevant landmark publications. We
also apply our approach to the task of discovering drugs that may be repurposed for reducing blood glucose. In both
cases, we show that our method is able to reproduce sufficient sets of defined factors and many relevant drugs within
the top hits, suggesting that our method will likely be useful in accelerating the discovery process.
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The KinderMiner Algorithm
Algorithm 1 breaks KinderMiner down step-by-step. At a high level, KinderMiner ranks a list of target terms by their
association with a specified key phrase. It does this via keyword matching and document counting within a specified,
relevant, searchable text corpus.
Algorithm 1 The KinderMiner algorithm.
Input: Corpus,TargetTerms,KeyPhrase,PThreshold
topTerms = {}
articleTotal = ArticleCount(Corpus)
kpTotal = ArticleCountWith(Corpus,KeyPhrase)
for term ∈ TargetTerms do
targKP = ArticleCountWithBoth(Corpus, term,KeyPhrase)
targNoKP = ArticleCountWith(Corpus, term)− targKP
noTargKP = kpTotal − targKP
noTargNoKP = articleTotal − targKP − targNoKP − noTargKP
p = OneSidedFisherExact(targKP ,noTargKP , targNoKP ,noTargNoKP)
if p < PThreshold then
topTerms = topTerms ∪ term
end if
end for
sortedTerms = SortByKeyPhraseAndTermRatio(topTerms)
return sortedTerms
First, KinderMiner requires a large corpus of documents for querying. While we focus on corpora of scientific litera-
ture, the corpus could also be a collection of plain text patient records taken from an electronic health record, a twitter
feed, blog posts, or any other large indexed collection of plain text documents. The corpus must be queryable for
document counts with exact matching of words and phrases. For evaluation purposes, it is also useful if the document
queries can be date censored, reducing counts of documents to only those that have been published within a specified
date range. This is not required, however.
Second, the user must specify a list of target terms to be ranked by their association with a specified key phrase. For
example, for one of our cell reprogramming applications, we specify a list of transcription factors and rank them by
their association with the key phrase “embryonic stem cell.” The goal of this query is to identify the factors necessary
for inducing an embryonic stem cell-like state. See Figure 1 for a more visual representation of this set of queries.
Next, for each target term, KinderMiner queries the corpus for documents that contain both, either, and neither the
target term and the key phrase, producing a contingency table of document counts. KinderMiner then performs a
one-sided Fisher’s exact test on the resultant contingency table, and filters out target term, key phrase pairs that do not
meet a prespecified significance level. KinderMiner uses the one-sided Fisher’s exact test to assess significance only
in the direction that there are more articles that contain both key phrase and target.
Finally, the selected target terms are ranked by the ratio of documents containing both the target term and the key
phrase, over the total of those containing the key phrase; that is, they are ranked by the proportion of documents
containing the target term that also contain the key phrase.
A great deal of work has been devoted to mining the biomedical literature. Our simple approach is related to prior
work on co-occurrence statistics and relationship extraction3,4 which often constrains search to particular types of
relationships or relies on more sophisticated techniques such as part-of-speech tagging and named entity recognition.
KinderMiner simply constrains the search space by relying on exact text matches to an input key phrase and target
terms. Of course, KinderMiner could almost certainly benefit from NLP techniques such as text normalization and
named entity recognition. Nevertheless, our goal with this work is to address whole literature information extraction
using the simplest approach we can imagine to rank potential associations, using readily available tools and sources
of data, and requiring little to no data annotation or processing. Despite its lack of sophistication, we find that our
approach performs well when presented with a large corpus.
In the next two sections, we motivate two different applications, cell reprogramming and drug repositioning respec-
Figure 1: Visual example of KinderMiner, with contingency table and associated Fisher’s Exact Test (FET) analysis
of the key phrase “embryonic stem cell” and the target term “NANOG.” Target terms are filtered by significance of
co-occurrence with the key phrase and then sorted by the co-occurrence ratio.
tively, and evaluate the KinderMiner algorithm in the context of these applications. We selected these particular
applications not only for their significance to science and medicine, but also because of the availability of reasonable
ground truth against which we can compare KinderMiner’s findings.
Cell Reprogramming Applications
An increasingly common task in modern biology is the process of taking cells of one type and reprogramming them
to exhibit the characteristics of another cell type. Reprogramming in this case often involves introducing a set of
transcription factors that put the source cells on track to behave like a different target cell type. A particularly important
example of reprogramming is that of somatic cells to an induced pluripotent stem (iPS) cell as iPS cells behave like
embryonic stem cells, wherein they have the potential to differentiate into nearly all fetal or adult cell types.5,6,7,8
Reprogramming can also be accomplished through transdifferentiation, which is when one somatic cell type is directly
converted into another somatic cell type.9 Reprogramming is important because researchers often need particular cell
types to create models, study the effects of disease, develop therapies, or perform basic science, but primary cells of
certain types are not always available in abundant quantities, if at all.
Altering the expression of transcription factors is also useful in the maturation of cells. For instance, methods exist
for differentiating and culturing immature hepatocytes, the main cells of the liver responsible for metabolism of drugs
and toxins, but these cells are difficult to mature. Immature hepatocytes cannot serve as reasonable surrogates for
hepatocyte function, drug toxicity, or metabolism. Recent publications10,11 describe methods for partial maturation
of hepatocytes using transcription factors. For similar reasons, having methods for differentiating cardiomyocytes,
muscle cells of the heart, is useful, and transcription factor sets for differentiating cells into cardiomyocytes have
recently been described.12,13
Determining a set of important transcription factors for converting one cell type into another is, however, a challeng-
ing task that involves a great deal of domain expertise as well as trial and error. There are roughly 2,000 transcription
factors to choose from,14 and researchers must rely on their reading of the literature and intuition to decide which
combinations to try and in what order. This search is time consuming, and we propose that our algorithm can assist
researchers by accelerating the trial and error process. Instead of trying combinations from the entire list of transcrip-
tion factors based on intuition, researchers can prioritize their experiments by exploring a much smaller number of
possible combinations from only the top ranked factors provided by our algorithm.
To demonstrate our algorithm in this domain, we refer to three well-established sets of factors for reprogramming.
The first is for creating induced pluripotent stem cells (iPS cells), the second is for creating cardiomyocytes, and
the third is for the maturation of hepatocytes. We use our algorithm to mine scientific and medical literature and
rank a list of transcription factors by correlation with the key phrases “embryonic stem cell,” “cardiomyocyte,” and
“hepatocyte.” We then compare the top hits in each list with the experimentally determined factors known to produce
cells representative of these cell states. For fairness, we censor the literature available to our algorithm by roughly two
years in advance of the earliest publications that demonstrate these conversions.
Drug Repurposing Application
Despite increases in R&D spending, the biopharmaceutical industry has struggled to improve cost and throughput of de
novo drug discovery.15 Due to advances in key technologies and the increasing availability of data, drug repositioning,
the detection of new uses for existing drugs, has become more feasible.16 Furthermore, repositioned drugs do not
require a costly development process and can reach clinical trials much faster than traditionally developed drugs.
These advantages have led repositioned drugs to constitute approximately 30% of drugs and vaccines newly approved
by the US Food and Drug Administration17.
There have been several computational drug repositioning (CDR) approaches proposed. Computational methods often
rely on heterogeneous data sources containing genetic and phenotypic information, drug molecular structure, elec-
tronic health records, or plain-text literature as we do here.16,18,19 We propose that our algorithm is a useful addition
to the CDR toolbox, despite being far simpler than other methods.
To demonstrate our algorithm in this domain, we focus on the task of identifying drugs that may reduce blood glucose.
We use our algorithm to mine the literature and rank a list of drugs and devices by correlation with the key phrase
“hypoglycemia” (i.e. low blood sugar). We manually assess how well our method is able to identify drugs and devices
that are specifically used to treat diabetes in the top hits, and then assess the potential of those top hits that are not
specifically for treatment of diabetes. We do not censor the date for this task.
Materials and Methods
For our experiments, we used the Europe PMC (EPMC) corpus.20 We implemented our queries with EPMC’s RESTful
API, using the profile search module with counts coming taken from the ALL publication type. We form our queries
using quoted, exact matches for both the target terms and key phrases, and we use the FIRST PDATE parameter to
censor publication year from 1900 through the specified year. For example, a query for co-occurrence of the term
NANOG and key phrase “embryonic stem cell,” censored to the end of 2004, would appear as follows:
‘‘NANOG’’ AND ‘‘embryonic stem cell’’ AND (FIRST PDATE:[1900-01-01 TO
2004-12-31])
At time of writing, the EPMC corpus contains a total of approximately 27.5 million publications. Approximately 20
million of the articles were published during or before 2008 and 17 million were published during or before 2004.
For our cell reprogramming applications, we query our lab’s list of 2,243 transcription factors against the key phrases
“embryonic stem cell,” “cardiomyocyte,” and “hepatocyte.” We use a one-sided FET p-value threshold of 1 × 10−5.
We collect the top 20 transcription factors from each of these queries and use two standards for comparison. First,
we search our top factors for factors from landmark publications that have previously been shown experimentally to
reprogram somatic cells to iPS cells, cardiomyocytes, and to partially mature hepatocytes. Specifically, the relevant
factors we consider for iPS cells are MYC, KLF4, LIN28, NANOG, POU5F1, and SOX2.6,8,7 The relevant factors
we consider for cardiomyocytes are GATA4, HAND2, MEF2C, NKX2-5, and TBX5.12,13 The relevant factors for
hepatocyte maturation are GATA4, HNF1A, FOXA3, FOXA2, HNF4A, CEBPB, and MYC.10,11
Second, we identify our top selected transcription factors that are also indicated as being relevant by the Mogrify
algorithm, a state-of-the-art algorithm to predict transcription factors for reprogramming between several cell types.21
Mogrify starts from gene expression data to score differentially expressed genes between cell types of interest and
background expression levels. It then combines these differential expression scores with regulatory network infor-
mation to rank transcription factors in each cell type by regulatory influence. Finally, Mogrify selects optimal sets
of transcription factors with the greatest regulatory influence over differentially expressed genes in a given target cell
type in comparison to a given starting cell type. Importantly, Mogrify requires a large amount of processed data that
may not be readily available and would be costly and time prohibitive to collect.
For the Mogrify comparison, we collect the complete lists of predicted transcription factors from http://www.
mogrify.net. For the iPS cell comparison, we use the conversion between dermal fibroblast and H9 embryonic
stem cells. For the cardiomyocyte comparison, we use the conversion between dermal fibroblast and heart - adult. For
the hepatocyte comparison, we use the conversion between dermal fibroblast and liver - adult.
For the iPS cell queries, we censor the publication date range through the end of the year 2004. This time frame
roughly corresponds to two years prior to the first publications on direct reprogramming in mouse cells.6 For the
cardiomyocyte queries, we censor the publication date range through the end of the year 2008, which also corresponds
to two years prior to the first major publications on cardiomyoctye reprogramming in mice.12 We censor to the year
2009 for the hepatocyte applications as it corresponds to roughly two years prior to the first major publication on
induction of functional hepatocytes from mouse fibroblasts.10
To evaluate our algorithm on the drug repositioning application, we query the same list of 2,609 drugs and devices
used by Kuang et al.18 against the key phrase “hypoglycemia” (low blood glucose). Again, we use a p-value threshold
of 1× 10−5. Note that we use an exact match of drug names in this case (e.g. Glucotrol and Glucotrol XL are treated
as different) even though there may be multiple names for the same drug. To evaluate our method, we first manually
annotate the top 50 hits as either advertised specifically to treat diabetes or not. We then compare those that were
not identified as diabetes drugs to a curated list of drugs22 that are known to cause hypoglycemia, hyperglycemia, or
both, reporting those correctly and incorrectly identified as reducing blood glucose. Finally, we mark the top hits that
also match hits in the full list of drugs and devices predicted to reduce blood glucose by the state-of-the-art approach
proposed by Kuang et al. using electronic health records.18 Kuang et al. extend the self-controlled case series model23
to handle continuous numeric responses. The self-controlled case series, which has been widely used for detecting
adverse drug events, divides patient time-course data into control and risk periods corresponding to periods before and
after exposure to a drug. Patients thus serve as their own control cases and relative incidence of adverse events can be
measured in the control and risk periods. Importantly, this approach requires a large amount of time-course electronic
health record data, which is difficult to acquire.
Results
Table 1(a) shows the top 20 ranked transcription factors from our query using a list of 2,243 transcription factors
and the key phrase “embryonic stem cell,” censored to a publication date range through 2004. Factors that match the
landmark papers for producing iPS cells are highlighted gray, and factors that match Mogrify’s list of predicted factors
are marked with *. Note that our naive approach is able to reproduce a sufficient list of factors (NANOG, POU5F1,
and SOX2) for direct reprogramming24 in the top 12 hits. Additionally, five of the top 20 match the list of 70 factors
produced by Mogrify.
Table 1(b) shows the top 20 ranked hits from our query using a list of transcription factors and the key phrase “car-
diomyocyte,” censored to a publication date range through 2008. Again, factors that match the landmark papers for
direct reprogramming to cardiomyocytes are highlighted in gray, and factors that match Mogrify’s list of predicted
factors are marked with *. Similar to the iPS cell query, our approach reproduces the complete list of early published
transcription factors in the first nine hits, and nine of the top 20 hits match the list of 57 factors predicted by Mogrify.
Table 1(c) shows the top 20 ranked hits from our query using a list of transcription factors and the key phrase “hepa-
tocyte,” censored to a publication date range through 2009. Again, factors that match the landmark papers for direct
reprogramming to hepatocytes are highlighted in gray, and factors that match Mogrify’s list of predicted factors are
marked with *. KinderMiner successfully reproduces four of the six factors for maturation from the landmark litera-
ture, and nine of the top 20 hits match the 27 predicted by Mogrify.
Table 2 shows the top 50 drugs and devices ranked by our method as being relevant to hypoglycemia (low blood
sugar). Drugs that are advertised specifically to treat diabetes are not highlighted. The highlighted drugs are not
specifically advertised to treat diabetes. Drugs highlighted green are labeled as drugs that may reduce blood sugar,
drugs highlighted red may increase blood sugar, and drugs highlighted gray are not present in our labeled list.22
Perhaps unsurprisingly, 43 of our top 50 hits are specifically for treatment of diabetes, due in part to the abundance of
diabetes drugs and various brand names thereof. We note that the hit premeal is likely a result of correlation to premeal
insulin. These 43 hits are a positive result as they suggest that our method successfully finds relevant correlations, but
the more interesting hits are those that are not diabetes drugs as our goal is to reposition drugs. Of the seven hits that
are not specifically diabetes drugs, Zestoretic, Avalide, and Demadex have been shown to potentially increase blood
glucose, whereas Zebeta, Tiazac, and Calan SR have been shown to potentially decrease blood glucose. Tequin is not
Table 1: Top 20 hits for each of our cell reprogramming queries. Hits that match the landmark papers are highlighted
in gray, and hits that match transcription factors predicted by Mogrify are marked with *.
(a) Transcription factors - “embryonic stem cell” - 2004
Term Term + KP Term Co-occurCount Count Ratio
*NANOG 15 59 0.254
*UTF1 5 25 0.200
CBX4 2 21 0.095
*POU5F1 24 272 0.088
EZH1 2 25 0.080
SOX1 8 103 0.078
IRX4 2 26 0.077
*FOXD3 4 54 0.074
MYF6 5 79 0.063
HOXB4 8 158 0.051
LMO2 12 240 0.050
*SOX2 11 230 0.048
EOMES 3 65 0.046
LMX1B 5 112 0.045
LHX2 3 76 0.040
HOXD9 3 78 0.039
HOXD11 3 80 0.038
OTX1 5 140 0.036
HAND1 4 117 0.034
HOXB3 3 88 0.034
(b) Transcription factors - “cardiomyocyte” - 2008
Term Term + KP Term Co-occurCount Count Ratio
MESP1 26 89 0.292
THRAP1 4 15 0.267
*TBX20 30 114 0.263
*GATA4 302 1294 0.233
*NKX2-5 122 528 0.231
*TBX5 104 481 0.216
GATA5 40 194 0.206
*MEF2C 151 825 0.183
*HAND2 52 297 0.175
CSRP3 8 46 0.174
IRX4 10 64 0.156
HDAC9 26 179 0.145
NFATC4 23 173 0.133
*IRX5 8 68 0.118
MKL2 5 43 0.116
ISL1 51 470 0.109
*GATA6 55 526 0.105
*HAND1 30 292 0.103
HES2 6 60 0.100
TBX18 7 73 0.096
(c) Transcription factors - “hepatocyte” - 2009
Term Term + KP Term Co-occurCount Count Ratio
HNF1A 781 849 0.920
HNF1B 639 699 0.914
*HNF4A 466 596 0.782
*ONECUT1 105 140 0.750
HNF4G 23 36 0.639
*FOXA3 137 217 0.631
ONECUT3 6 10 0.600
*FOXA1 313 571 0.548
*FOXA2 523 1055 0.496
TCF2 136 276 0.493
MLX 325 687 0.473
*NR0B2 54 138 0.391
*NR1I3 66 171 0.386
*NR1H4 66 171 0.386
HMBOX1 5 13 0.385
NR1I2 74 200 0.370
ONECUT2 14 40 0.350
TCF1 137 460 0.298
*CREB3L3 7 25 0.280
CUTL2 13 47 0.277
in our labeled list. It is an antibiotic that has been shown to increase patient risk of dysglycemia (either hypoglycemia
or hyperglycemia).25
Overall, in all of our evaluation tasks, our method finds numerous relevant hits and demonstrates overlap with the
results of far more sophisticated methods designed specifically for the separate tasks presented.
Conclusions and Future Work
In this work, we present a simple and general text mining method for predicting pairwise associations between a key
phrase and target terms. We demonstrate the use of this method for identifying transcription factors that are important
for three cell reprogramming tasks and for discovering candidate drugs for alternative uses. In both of our applica-
tion domains, we find that KinderMiner identifies numerous relevant hits and overlaps with state-of-the-art methods
designed specifically for each domain. In historically censored searches of factors for reprogramming cell states, Kin-
derMiner highly ranks transcription factors that would, years later, be shown to be important for reprogramming to
Table 2: Top 50 drug and device hits for our drug repositioning query against the key phrase “hypoglycemia.” Hits that
are diabetes drugs are not highlighted. Hits that are not diabetes drugs, but which are known to decrease blood sugar
are highlighted in green, and hits that increase blood sugar are highlighted in red. Hits that are not diabetes drugs, but
were also not in our labeled list, are highlighted in gray. Hits that are exact matches to those in Kuang et al.18 are
marked with *.
Drug Drug + KP Drug Co-occurCount Count Ratio
GLYBURIDE MICRONIZED 3 4 0.750
GLYNASE 16 27 0.593
MICRONASE 24 41 0.585
NOVOLIN N 28 48 0.583
STARLIX 26 46 0.565
TOLINASE 14 26 0.538
GLIPIZIDE XL 7 13 0.538
*GLUCOTROL XL 15 28 0.536
*INSULIN DETEMIR 547 1107 0.494
PREMEAL 477 975 0.489
SUBCUTANEOUS INSULIN INFUSION PUMP 37 76 0.487
*INSULIN ASPART 723 1509 0.479
*INSULIN LISPRO 717 1515 0.473
NPH INSULIN 787 1665 0.473
PRECOSE 31 66 0.470
PRANDIN 27 59 0.458
LANTUS 290 640 0.453
*GLUCOTROL 41 91 0.451
NOVOLOG 90 203 0.443
ZESTORETIC 3 7 0.429
*HUMALOG 210 495 0.424
*AMARYL 47 113 0.416
INSULIN NPH 281 691 0.407
GLYBURIDE-METFORMIN 46 117 0.393
REGULAR INSULIN 1182 3048 0.388
*GLIMEPIRIDE 935 2487 0.376
BYETTA 136 370 0.368
ZEBETA 4 11 0.364
HUMULIN N 50 140 0.357
*GLUCOPHAGE XR 16 45 0.356
PRAMLINTIDE ACETATE 21 60 0.35
JANUVIA 87 252 0.345
LIRAGLUTIDE 885 2589 0.342
INSULIN REGULAR HUMAN 41 121 0.339
AVALIDE 3 9 0.333
DEMADEX 3 9 0.333
NATEGLINIDE 351 1098 0.320
REPAGLINIDE 458 1486 0.308
AVANDAMET 17 56 0.304
*EXENATIDE 1136 3843 0.296
*GLIPIZIDE 669 2278 0.294
GLUCAGEN 29 99 0.293
*BLOOD-GLUCOSE METER 539 1926 0.280
WELCHOL 22 79 0.278
TIAZAC 4 15 0.267
GLUCOVANCE 18 68 0.265
TEQUIN 11 43 0.256
NOVOLIN R 68 270 0.252
NOVOLIN 143 570 0.251
CALAN SR 4 16 0.25
cell states of interest, thus providing a short, ordered list of candidates for biologists that would have greatly simplified
the challenging combinatorial task they faced. Importantly, the domain-specific approaches require domain-specific
data, whereas KinderMiner only requires an indexed text corpus. We argue that our method is a valuable new tool that
can be used to help prioritize research directions despite its naivete´. Furthermore, we anticipate that our method may
prove valuable in domains other than biomedicine by mining other large plain text corpora.
We view the simplicity of KinderMiner as a strength, but this simplicity also leads to limitations. For example,
KinderMiner does not explicitly implement any actual natural language processing. Thus, terms like the transcription
factor T (Brachyury) are likely to match many articles that do not reference the T gene, but may in fact be matches
to middle initials or similar. We do not observe this particular phenomenon in our lists of top 20 hits presented here,
but we anticipate that this may be a problem for other queries. While we believe there is value in the simplicity of our
method, we expect that the addition of techniques such as text normalization and named entity recognition may help
alleviate this issue and, therefore, propose it as future work.
Furthermore, we observe that some of our queries have low total counts of articles for sorting by ratio. For example,
THRAP1 in Table 1(b) counts a total of 15 articles that contain the term, four of which contain both the term and key
phrase. This may pose a greater challenge when using smaller corpora, or when querying terms or key phrases that
are relatively new within the literature. A query that counts a total of four articles, three of which have both term and
key phrase may be ranked well by ratio, but is unlikely to actually represent compelling evidence of association. In
general, there will always be a horizon of discovery defined by the quantity of published literature for particular key
phrases and target terms, but we will explore the use of thresholding, pseudocounts, and other Bayesian approaches to
modulate the rank of such cases in future work.
Finally, we note that constructing a search engine around large corpora is non-trivial. We were fortunate with our
applications in that Europe PMC offers a web API on which we built KinderMiner, but not all corpora will afford
such convenience. We do not propose any specific suggestions for how to address this issue, but instead expect that
time will assist with the continued democratization of search tools (e.g. Apache Lucene and SOLR). We anticipate
that the availability of easy-to-use software packages will continue to grow, and we propose evaluating applications of
KinderMiner using such software on open data as future work.
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